Inhibrx Biosciences (INBX) financial statements
Inhibrx Biosciences reported revenue of $1M in fiscal 2025, down 15.0% a year over 2 years.
Net income was -$140M and the operating margin -10386.5%, against -12178.9% in 2023.
Free cash flow was -$130M.
The diluted share count rose 31% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Inhibrx Biosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $2M | $200,000 | $1M |
| Research and development | $192M | $204M | $113M |
| Selling, general and admin | $29M | $128M | $23M |
| Operating income | -$219M | -$331M | -$135M |
| Interest expense | $32M | $13M | $12M |
| Pre-tax income | -$240M | $1.7B | -$140M |
| Income tax | $3,000 | $2,000 | $2,000 |
| Net income | -$241M | $1.7B | -$140M |
| EPS (diluted) | -$20.48 | $112.62 | -$9.04 |
| Diluted shares | 12M | 15M | 15M |
| Operating margin | -12178.9% | -165724.0% | -10386.5% |
| Net margin | -13408.9% | 843786.0% | -10773.5% |
Balance sheet
Fiscal years, from Inhibrx Biosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $278M | $153M | $124M |
| Total current assets | $295M | $160M | $133M |
| Property, plant and equipment | $6M | $6M | $4M |
| Total assets | $308M | $181M | $146M |
| Total current liabilities | $56M | $41M | $34M |
| Long-term debt | $207M | $0 | $101M |
| Total liabilities | $264M | $47M | $138M |
| Shareholders' equity | $44M | $134M | $8M |
| Net debt | -$71M | -$153M | -$24M |
Cash flow
Fiscal years, from Inhibrx Biosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$193M | -$194M | -$130M |
| Capital spending | $5M | $3M | $31,000 |
| Free cash flow | -$198M | -$197M | -$130M |
| Stock-based compensation | $25M | $59M | $11M |
| Free cash flow margin | -10994.6% | -98503.0% | -9986.5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for INBX.
Open INBX in InvestinglyQuestions
What was Inhibrx Biosciences's revenue in 2025?
$1M in fiscal 2025, from its 10-K filing.
How much free cash flow does Inhibrx Biosciences generate?
-$130M in fiscal 2025 (operating cash flow minus capital spending).
From Inhibrx Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.